Pfizer Avoids Off-Label Marketing Suit Over Geodon, Zyvox

Law360, Washington (June 28, 2012, 6:06 PM ET) -- A Texas federal judge on Thursday threw out a Blue Cross Blue Shield operator's off-label marketing suit claiming Pfizer Inc. misrepresented its antipsychotic drug Geodon and antibiotic Zyvox, saying the operator didn't show economic injury from Pfizer's actions.

District Judge Michael H. Schneider agreed with U.S. Magistrate Judge Caroline M. Craven, who recommended Health Care Services Corp.'s case be dismissed because it couldn't show that Pfizer's actions caused financial loss or caused doctors to prescribe the drugs for off-label use when they otherwise would not have....
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required